Acumen Pharmaceuticals, Inc.
ABOS
$2.99
-$0.18-5.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -32.72M | -20.74M | -25.14M | -26.45M | -40.95M |
| Total Depreciation and Amortization | 45.00K | 46.00K | 45.00K | 47.00K | 47.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.86M | 2.30M | 3.00M | 2.94M | 2.80M |
| Change in Net Operating Assets | 11.74M | -5.74M | 2.99M | -7.03M | 6.28M |
| Cash from Operations | -18.08M | -24.13M | -19.10M | -30.49M | -31.83M |
| Capital Expenditure | -- | -- | 0.00 | 0.00 | -9.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 26.00M | -13.81M | 26.25M | 40.51M | 38.49M |
| Cash from Investing | 26.00M | -13.81M | 26.25M | 40.51M | 38.48M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 35.89M | 2.00K | 0.00 | 0.00 |
| Repurchase of Common Stock | -278.00K | -149.00K | 0.00 | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -278.00K | 35.74M | 2.00K | 0.00 | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7.65M | -2.19M | 7.16M | 10.02M | 6.65M |